Merck, also recognized as MSD in countries other than the United States and Canada, revealed the finalization of the acquisition of CN201 from Curon Biopharmaceutical (Curon), a new experimental bispecific antibody in clinical development for...
The World Health Organization (WHO) issued guidance on how to enhance the organization and supervision of clinical trials in nations with diverse income levels. This guidance seeks to enhance country-led R&D ecosystems in order to progress health...
Innate Pharma SA, a worldwide biotech firm in clinical stages advancing cancer immunotherapies, reported that the FDA has approved its IND application for a phase 1 clinical trial of IPH4502, a unique topoisomerase I inhibitor ADC targeting...
The government is considering overseeing the quality of imported medical devices through a risk-based method in which random samples will be selected for quality testing, with entire shipments of critical diagnostic kits being...
Suzhou-based CD Biopharma, a fast-growing biotech company in the clinical stage, has been approved by the FDA for its CD-001 Investigational New Drug (IND) application, marking the start of a phase I human trial...
InnoCare Pharma, a top biopharmaceutical company specializing in cancer and autoimmune disease treatments, declared the approval of the Investigational New Drug (IND) to carry out a clinical trial of ICP-248, a B-cell lymphoma-2 (BCL2) inhibitor...
Stealth BioTherapeutics Inc., a biotech company in clinical stage, and Friedreich’s Ataxia Research Alliance (FARA) have announced that Stealth has received the Kyle Bryant Translational Research Award from FARA to study SBT-589 in Friedreich’s...
Efforts to replace medical inhalers with near-zero emission alternatives have advanced, as AstraZeneca announced the completion of the clinical program for a new propellant with 99.9% lower Global Warming Potential (GWP) than those used in current...
Sun Pharma and Israel-based Moebius Medical announced that the USFDA has granted fast track designation (FTD) to their novel non-opioid therapy, MM-II, designed to address osteoarthritis knee pain. This designation allows for an expedited review p...
.JPG)
Nxera Pharma Co., Ltd. is set to get a US$35 million payout from Neurocrine Biosciences (‘Neurocrine’) for the Phase 2 trial success with NBI-1117568 (NBI-‘568) in adults with schizophrenia, as disclosed on 28 August 2024. Recognition of the US$35...
, CDSCO.jpg)
